PT  - JOURNAL ARTICLE
AU  - Held, Matthias
AU  - Jany, Berthold H
TI  - Pulmonary Hypertension in COPD
AID  - 10.4187/respcare.02058
DP  - 2013 Aug 01
TA  - Respiratory Care
PG  - e86--e91
VI  - 58
IP  - 8
4099  - http://rc.rcjournal.com/content/58/8/e86.short
4100  - http://rc.rcjournal.com/content/58/8/e86.full
AB  - Pulmonary hypertension (PH) is a common consequence of COPD. It has been speculated that patients showing serious PH and vascular remodeling without severe airway obstruction might benefit from vasoactive treatment. There is no approved drug available for COPD-induced PH. Most trials assessing the efficacy of vasoactive drugs in PH have had a follow-up of 12–16 weeks. We report on 4 subjects with COPD and PH. Pulmonary arterial hypertension associated diseases and pulmonary embolism were ruled out. PH persisted despite optimized treatment of underlying COPD and comorbidities, so bosentan was started in all 4 subjects. With bosentan the mean pulmonary artery pressure improved. The average gains in 6-min walk distance at 2–3 months and 8–9 months were 36 m and 145 m, respectively. The maximum gains in 6-min walk distance of the individual subjects were at the 9th, 13th, and 18th month. Oxygenation was stable, and no side effects were observed. We suggest from this experience that in clinical trials of PH in COPD, a follow-up of 16 weeks might cause underestimation of the treatment effects.